A number of studies have documented mechanisms whereby crosstalk between AR and ER exists, with most evidence supporting a model in which AR inhibits ER signaling through a variety of mechanisms—providing a biological basis for why AR positivity may associate with improved outcomes in ER positive breast cancers. The gene discussed is ESR1; the disease is breast cancer.